Dr. Laura A Kilty, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3960 Fax: 607-547-6574 |
Dr. Kamran I Chaudhri, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3456 |
Dr. Charles B Deichman, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3909 Fax: 607-547-6325 |
Dr. Rafael Medina, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-6960 Fax: 607-547-6574 |
Dr. John A Leon, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3960 Fax: 607-547-6574 |
Dr. Christopher Derek Ratliff, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3960 Fax: 607-547-6325 |
News Archive
Many neurology pathologies cause irreversible loss of neurons. They are mostly the so-called neurodegenerative diseases although there exist other causes for a focal loss of neurons, as it is the case in strokes or traumatic brain injuries. All these pathologies lack nowadays of an efficient treatment not being possible to regenerate dead neurons. In fact, although the brain has the ability to regenerate as many studies has proved, this regeneration is very low, ranging from 0.2% to a maximum of 10% depending on the type of injury and the damaged area.
Illumina, Inc. today announced its next generation of iSelect custom genotyping products that allow researchers to design custom arrays containing from 3,000 up to 1,000,000 markers, with the flexibility to add supplemental content to their array designs.
Scientists hope to gain insights into a range of age-related ailments, such as dementia, by examining the behaviour of proteins thought to trigger the conditions.Researchers from the University of Edinburgh are to study proteins found in the body to try to find out why these molecules can sometimes clump together as people get older. The clumps interfere with the biological processes that enable the body to function healthily.
Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.
A team of researchers led by neuroscientists at Harvard Medical School has successfully used acupuncture to tame cytokine storm in mice with systemic inflammation.
› Verified 2 days ago